Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 848 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hyperlipidemia Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

NCT06592339
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MK-0616
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism

NCT02366156
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, Low Dose Grape Blend, High Dose Grape Blend
Dietary Supplement
Lead sponsor
Access Business Group
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Metformin on Blood Vessel Structure and Function

NCT00105066
View directory record Official record
Conditions
Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome

NCT01010841
View directory record Official record
Conditions
Metabolic Syndrome, Overweight, Obesity, Hypercholesterolemia
Interventions
UltraMealPlus 360 (Medical food), Low-glycemic-load diet
Dietary Supplement · Other
Lead sponsor
MetaProteomics LLC
Industry
Eligibility
20 Years to 75 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

NCT00477594
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

NCT01163851
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
4 mg/kg, 0.5 mg/kg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
5
States / cities
Peoria, Arizona • Phoenix, Arizona • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 4 Interventional

SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia

NCT00194402
View directory record Official record
Conditions
Dyslipidemia
Interventions
Slo-Niacin, atorvastatin
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

NCT03060577
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
Interventions
Inclisiran, Evolocumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 3 Interventional

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

NCT03398005
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
CaPre, Placebo
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Not applicable Interventional

A Defined, Plant-based, 4-week Dietary Intervention Reduces Lp(a) and Other Atherogenic Particles

NCT03172611
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Dietary Intervention
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 20, 2026, 2:26 PM EDT
Not listed Phase 3 Interventional

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
AKR-963
Drug
Lead sponsor
Trygg Pharma, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 20, 2026, 2:26 PM EDT
Active, not recruiting Phase 3 Interventional

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756
View directory record Official record
Conditions
Arteriosclerosis, Hypercholesterolaemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
14,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
132
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Not applicable Interventional

Reducing Disparities in Primary Prevention of Cardiovascular Disease

NCT01610609
View directory record Official record
Conditions
Cardiovascular Diseases, Cholesterol, LDL
Interventions
Population Health Management Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
35 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Flagstaff, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

NCT00903409
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • Encinitas, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 20, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

NCT07199309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
MAR001, Placebo
Drug
Lead sponsor
Marea Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 20, 2026, 2:26 PM EDT
Not yet recruiting Not applicable Interventional

2-HOBA Supplementation in People With Elevated Lipoprotein(a)

NCT07198009
View directory record Official record
Conditions
Hyperlipidemia, Elevated Lp(a)
Interventions
2-HOBA (Hobamine)
Dietary Supplement
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Body Worlds 3 Nutrition Display

NCT00669500
View directory record Official record
Conditions
Obesity, Hyperlipidemia
Interventions
Lifestyle intervention
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Not listed
Enrollment
3,188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 28, 2011 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

NCT00166036
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
Interventions
Atorvastatin, Pravastatin
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 20, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

NCT02634606
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 20, 2026, 2:26 PM EDT
Recruiting Not applicable Interventional

Multicomponent Intervention Study- Blood Donors With High Cholesterol

NCT05693701
View directory record Official record
Conditions
Lipid Metabolism Disorder
Interventions
Implementation Strategy Bundle, Usual care notification
Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease

NCT03161327
View directory record Official record
Conditions
Peripheral Artery Disease, Amputation, Smoking, Diabetes, Hypercholesterolemia, Hypertension
Interventions
ABI using QuantaFlo™
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Short-term Effects of Leptin in People With Lipodystrophy

NCT01778556
View directory record Official record
Conditions
Lipodystrophy
Interventions
Metreleptin
Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
14 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Butter & MCT Oil on Lipoproteins - A RCT

NCT02611102
View directory record Official record
Conditions
Hyperlipidemia
Interventions
MCT oil + Butter in Coffee
Dietary Supplement
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Clinical Inertia in Diabetes Care

NCT00272402
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Hyperlipidemia
Interventions
Cognitive Behavioral Intervention, Office System Redesign Intervention
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 20, 2026, 2:26 PM EDT